ZURICH/BERLIN, July 31 (Reuters) - The Swiss blue-chip SMI was seen opening 0.4 percent higher at 9,932 points on Wednesday, according to premarket indications by bank Julius Baer.
Here are some of the main factors that may affect Swiss stocks:
LafargeHolcim more than doubled net profit during the first half of 2019, the world’s largest cement maker said on Wednesday, and confirmed its full year outlook.
The reinsurer on Wednesday posted a 5.3% fall in net profit in the first half of the year from a year earlier, with earnings damped by claims from natural catastrophes and claims related to the Boeing 737 MAX fleet.
The No. 2 Swiss bank on Wednesday posted its highest quarterly earnings in four years, confirming its 2019 profitability target after second-quarter earnings jumped 45%.
Roche and Spark Therapeutics announced another extension of the Swiss drugmaker’s $4.3 billion takeover offer for the U.S. gene therapy specialist as regulatory reviews in the United States and Britain continue.
* Medacta on Tuesday said it was entering the U.S. and Australian sports medicine markets with a lineup of surgical solutions.
SIG COMBIBLOC GROUP AG: Credit Suisse raises target price to 14.50 from 14.20 Swiss francs.
TRANSOCEAN: Credit Suisse cuts target price to $10 from $13. Evercore ISI cuts price target to $11 from $12. RBC cuts price target to $17 from $20. Jefferies cuts price target to $7.50 from $8.
DUFRY AG: Citigroup raises price target to 95 from 8 Swiss francs.
COSMO PHARMACEUTICALS NV: Jefferies cuts target price to 150 from 165 Swiss francs.
No major Swiss economic data scheduled (Reporting by Zurich newsroom and Berlin Speed Desk)